Sun Pharmaceutical Industries Croissance future
Future contrôle des critères 1/6
Sun Pharmaceutical Industries devrait augmenter ses bénéfices et son chiffre d'affaires de 12.7% et de 9.9% par an respectivement. Le BPA devrait croître de de 12.6% par an. Le rendement des capitaux propres devrait être 17% dans 3 ans.
Informations clés
12.7%
Taux de croissance des bénéfices
12.6%
Taux de croissance du BPA
| Pharmaceuticals croissance des bénéfices | 17.8% |
| Taux de croissance des recettes | 9.9% |
| Rendement futur des capitaux propres | 17.0% |
| Couverture par les analystes | Good |
| Dernière mise à jour | 12 Nov 2024 |
Mises à jour récentes de la croissance future
Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31
Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Recent updates
Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?
Nov 18Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
Oct 31We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease
Oct 21Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now
Aug 24Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next
Aug 06This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid
Jul 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth
Jun 30Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Jun 12Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year
May 25Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings
May 22Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet
Mar 13Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Feb 03Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today
Jan 05Getting In Cheap On Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Is Unlikely
Dec 18Is Now The Time To Put Sun Pharmaceutical Industries (NSE:SUNPHARMA) On Your Watchlist?
Oct 04Should You Be Adding Sun Pharmaceutical Industries (NSE:SUNPHARMA) To Your Watchlist Today?
Jul 03We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Can Manage Its Debt With Ease
Jun 15Is Sun Pharmaceutical Industries (NSE:SUNPHARMA) A Risky Investment?
Mar 14Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Increasing Its Dividend To ₹7.50
Feb 03These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Reasonably Well
Dec 09Does This Valuation Of Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Imply Investors Are Overpaying?
Oct 13These 4 Measures Indicate That Sun Pharmaceutical Industries (NSE:SUNPHARMA) Is Using Debt Safely
Sep 04Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's
Aug 05Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 3/31/2027 | 641,906 | 149,878 | 122,453 | 156,535 | 31 |
| 3/31/2026 | 586,579 | 132,950 | 106,830 | 135,859 | 36 |
| 3/31/2025 | 528,958 | 115,396 | 96,841 | 117,504 | 36 |
| 9/30/2024 | 503,077 | 110,541 | 107,739 | 127,155 | N/A |
| 6/30/2024 | 492,088 | 103,895 | N/A | N/A | N/A |
| 3/31/2024 | 484,969 | 95,764 | 99,332 | 121,350 | N/A |
| 12/31/2023 | 474,446 | 89,063 | N/A | N/A | N/A |
| 9/30/2023 | 463,049 | 85,485 | 96,498 | 116,171 | N/A |
| 6/30/2023 | 450,648 | 84,352 | N/A | N/A | N/A |
| 3/31/2023 | 438,857 | 84,736 | 28,738 | 49,593 | N/A |
| 12/31/2022 | 424,018 | 42,119 | N/A | N/A | N/A |
| 9/30/2022 | 410,239 | 41,047 | 24,284 | 40,183 | N/A |
| 6/30/2022 | 396,975 | 38,894 | N/A | N/A | N/A |
| 3/31/2022 | 386,545 | 32,727 | 74,895 | 89,845 | N/A |
| 12/31/2021 | 377,307 | 64,441 | N/A | N/A | N/A |
| 9/30/2021 | 367,044 | 62,378 | 67,751 | 82,511 | N/A |
| 6/30/2021 | 356,316 | 60,036 | N/A | N/A | N/A |
| 3/31/2021 | 334,981 | 29,038 | 50,002 | 61,704 | N/A |
| 12/31/2020 | 331,601 | 24,095 | N/A | N/A | N/A |
| 9/30/2020 | 324,782 | 14,706 | 33,332 | 47,270 | N/A |
| 6/30/2020 | 320,484 | 7,219 | N/A | N/A | N/A |
| 3/31/2020 | 328,375 | 37,649 | 50,128 | 65,548 | N/A |
| 12/31/2019 | 318,165 | 40,010 | N/A | N/A | N/A |
| 9/30/2019 | 314,018 | 43,293 | 26,411 | 43,521 | N/A |
| 6/30/2019 | 302,161 | 29,956 | N/A | N/A | N/A |
| 3/31/2019 | 290,659 | 26,654 | -10,164 | 21,965 | N/A |
| 12/31/2018 | 288,052 | 34,379 | N/A | N/A | N/A |
| 9/30/2018 | 277,182 | 24,380 | N/A | N/A | N/A |
| 6/30/2018 | 275,048 | 35,690 | N/A | N/A | N/A |
| 3/31/2018 | 264,155 | 20,957 | N/A | 39,072 | N/A |
| 12/31/2017 | 263,811 | 20,763 | N/A | N/A | N/A |
| 9/30/2017 | 276,530 | 31,827 | N/A | N/A | N/A |
| 6/30/2017 | 295,310 | 45,057 | N/A | N/A | N/A |
| 3/31/2017 | 313,081 | 69,644 | N/A | 70,822 | N/A |
| 12/31/2016 | 319,185 | 73,270 | N/A | N/A | N/A |
| 9/30/2016 | 311,431 | 74,000 | N/A | N/A | N/A |
| 6/30/2016 | 297,512 | 61,937 | N/A | N/A | N/A |
| 3/31/2016 | 281,086 | 45,457 | N/A | 66,859 | N/A |
| 12/31/2015 | 266,281 | 38,915 | N/A | N/A | N/A |
| 9/30/2015 | 264,670 | 28,702 | N/A | N/A | N/A |
| 6/30/2015 | 276,422 | 38,150 | N/A | N/A | N/A |
| 3/31/2015 | 273,920 | 45,394 | N/A | 56,157 | N/A |
| 12/31/2014 | 170,765 | 59,141 | N/A | N/A | N/A |
| 9/30/2014 | 170,835 | 60,202 | N/A | N/A | N/A |
| 6/30/2014 | 165,250 | 58,100 | N/A | N/A | N/A |
| 3/31/2014 | 160,804 | 31,415 | N/A | 39,592 | N/A |
| 12/31/2013 | 150,933 | 26,104 | N/A | N/A | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: La croissance des bénéfices prévue de SUNPHARMA ( 12.7% par an) est supérieure au taux d'épargne ( 6.7% ).
Bénéfices vs marché: Les bénéfices de SUNPHARMA ( 12.7% par an) devraient croître plus lentement que le marché Indian ( 18% par an).
Croissance élevée des bénéfices: Les bénéfices de SUNPHARMA devraient augmenter, mais pas de manière significative.
Chiffre d'affaires vs marché: Le chiffre d'affaires de SUNPHARMA ( 9.9% par an) devrait croître plus lentement que le marché de Indian ( 10.5% par an).
Croissance élevée des revenus: Le chiffre d'affaires de SUNPHARMA ( 9.9% par an) devrait croître plus lentement que 20% par an.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Le retour sur capitaux propres de SUNPHARMA devrait être faible dans 3 ans ( 17 %).